Model PROTAC - Proteolysis Targeting Chimera

PROTAC-Proteolysis targeting chimera is a technology that induces the Ubiquitin-Proteasome System (UPS) to degrade the target protein. When the target protein (Protein of Interest (POI)) is ubiquitinated by the ligase of E1, E2, E3, the proteasome recognizes that part of the protein and degrades the protein. PROTAC is composed of a protein of interest, a ligand that binds to the E3 ligase, and a linker that connects the two. PROTAC is emerging as a next-generation platform for new drug development that overcomes the problems of drug resistance and “Undruggable targets” of existing target therapies whose main purpose was to inhibit the function. Deargen discovers the structure of an optimized ligand and linker using a highly advanced AI solution, and is conducting research on anticancer target treatments through collaboration with leading companies in the PROTAC field.